INC Research Acquires MDS Pharma Services Phase II-IV operations

MDS has completed the divestiture of its phase II-IV operations to INC Research. Under the terms of the agreement, INC Research has acquired MDS Pharma Services’ phase II-IV operations, which includes approximately 800 employees who conduct clinical trials in more than 25 countries.

The company expects to provide additional detail with respect to the divestiture of its phase II-IV operations, together with the financial results for its fiscal third quarter .

The company said that its decision to sell its MDS Pharma Services, which consists of phase II-IV operations and Central Labs, are a result of its ongoing strategic review process.

Stephen DeFalco, President and CEO of MDS, said: The completion of this transaction supports our efforts to advance MDS Pharma Services’ top-three leadership position in the delivery of Early Stage services.